Lillys Triple Agonist, Retatrutide, Delivered Weight Loss of Up to an Average of 71.2 lbs Along With Substantial Relief From Osteoarthritis Pain in First Successful Phase 3 Trial. Press Release, December 11, 2025
Bone mass loss has also been a notable side effect
Course Highlights Discover how combining lifestyle modifications with GLP-1 receptor agonists can improve weight loss, glycemic control, and overall cardiometabolic health Examine the science behind GLP-1 receptor agonists, from their effects on insulin secretion and appetite regulation to next-generation agents like tirzepatide and orforglipron Learn best practices for patient education, dosing strategies, and interprofessional collaboration while addressing contraindications, adverse effects, and compounding warnings Introduction Obesity is a chronic and prevalent condition that impacts health, contributing to higher rates of morbidity and mortality
For positive-mode acquisition, mobile phase A was 100% LCMS-grade H 2 O with 10 mM ammonium formate and 0.125% formic acid
Talk with your prescribing provider and request an eating disorder-informed assessment